{
    "title": "R42960",
    "content": "The Hatch-Waxman Act of 1984 reformed patent and food and drug laws to balance innovation and competition in the pharmaceutical industry. Congressional focus has shifted to pharmaceutical patent litigation settlements, as brand-name companies must litigate to enforce their patents against generic competitors in federal courts. Pharmaceutical patent litigation settlements involve brand-name companies pursuing litigation in federal courts against generic competitors. These settlements may result in judgments of infringement, invalidity, or non-infringement, which can impact generic competition. Parties may choose to settle, with some agreements including cash payments from the brand-name company to the generic firm in exchange for not challenging patents or selling generic versions of the drug. These settlements are sometimes referred to as \"pay-for-delay\" agreements. Some observers term pharmaceutical patent settlements as \"pay-for-delay\" agreements. Views on reverse payment settlements vary, with some attributing them to specialized patent litigation procedures while others see them as anti-competitive. Congress requires notification of these settlements to antitrust authorities since 2003, but has not set substantive standards for assessing their validity. Judicial application of general antitrust principles determines the legality of these agreements, leading to varied outcomes in different cases. The U.S. Supreme Court decision in Federal Trade Commission v. Actavis, Inc. on reverse payment settlements established the \"rule of reason\" approach for evaluating their legality. Lower courts now face the challenge of applying this standard. Legislation in Congress, such as the Preserve Access to Affordable Generics Act (S. 214) and the FAIR Generics Act (S. 504), aims to address issues related to reverse payment settlements and introduce reforms to the Hatch-Waxman Act. The FAIR Generics Act (S. 504) aims to reform the Hatch-Waxman Act by reducing incentives for generic firms to settle with brand-name companies. This legislation is still pending. The report discusses innovation and competition policy issues related to pharmaceutical patent litigation settlements, including reverse payment settlements and their status under antitrust laws. It also highlights the process of submitting patent applications to the US Patent and Trademark Office for patent protection. The patent application process involves drafting a specification and claims that meet substantive standards set by the patent statute. Key criteria for patentability include novelty and nonobviousness, where the invention must not be fully anticipated by prior art to be considered novel and nonobvious. To meet the standard of nonobviousness, an invention must not have been readily within the ordinary skills of a competent artisan based on prior art. If granted, a patent allows exclusivity for twenty years, enabling inventors to practice their inventions or license others. This exclusivity allows inventors to recoup resources spent on discovery by charging higher prices, especially in industries like pharmaceuticals where generic competition can impact availability. The introduction of generic competition in the pharmaceutical industry provides lower-cost substitutes for innovative products. Patent owners must monitor competitors and may need to litigate to enforce their rights. While a patent grants proprietary interest, FDA approval is required to distribute a pharmaceutical product. Developers must demonstrate safety and efficacy through preclinical and clinical investigations for FDA marketing approval. The FDA evaluates test data in a New Drug Application (NDA) for marketing approval. Before the Hatch-Waxman Act, generic manufacturers had to file their own NDA. Some could use published literature for a \"paper NDA,\" but not all drugs had this option. Additional studies were sometimes requested by the FDA for safety and efficacy concerns. The Hatch-Waxman Act created an expedited pathway for generic drug approval, known as an Abbreviated New Drug Application (ANDA), to address concerns about the costly and time-consuming process of proving drug safety and efficacy for generic manufacturers. The Hatch-Waxman Act established the Abbreviated New Drug Application (ANDA) pathway for generic drugs, allowing generic manufacturers to demonstrate bioequivalence to pioneer drugs without extensive clinical data. This process helps avoid costs and delays associated with a full New Drug Application (NDA) and allows for quicker market entry after relevant patents expire. Additionally, patent proprietors can seek a maximum five-year extension to compensate for lost patent term during FDA approval. The Hatch-Waxman Act allows for a maximum five-year patent term extension to compensate brand-name firms for regulatory delays. This extension is limited to the approved use of the product. Special procedures are in place to resolve patent disputes between brand-name and generic drug manufacturers. The Hatch-Waxman Act established procedures for resolving patent disputes related to generic drug applications. NDA applicants must file a list of patents they believe would be infringed by generic drugs. These patents are listed in the \"Orange Book.\" Generic drug manufacturers must engage in a certification process for Orange Book-listed patents when seeking approval. The Hatch-Waxman Act established procedures for resolving patent disputes related to generic drug applications. Generic companies must provide certifications stating that the patent has expired, is invalid, or will not be infringed. Certifications are categorized as paragraph I, II, III, or IV. Approval for paragraph I or II certifications is immediate, while paragraph III requires waiting for the brand-name drug's patent to expire. Filing with a paragraph IV certification is considered an act of patent infringement. The Hatch-Waxman Act incentivizes challenges to pharmaceutical patents by granting a 180-day exclusivity period to the first generic applicant filing a paragraph IV certification. This provision aims to stimulate competition and potentially higher profits for the initial applicant. Following 2003 amendments to the Hatch-Waxman Act, a first paragraph IV ANDA applicant may lose its entitlement to the 180-day generic exclusivity period due to forfeiture events such as failure to market promptly or obtain FDA approval in a timely manner. This was intended to prevent the practice of 'parking' exclusivity and encourage prompt market entry by generic manufacturers. Generic firms filing a paragraph IV ANDA may face patent infringement suits from brand-name drug companies. If the NDA holder proves patent violation, an injunction may prevent the generic company from marketing the product until the NDA holder's patents expire. The generic firm may amend their ANDAs to replace paragraph IV certifications with paragraph III certifications. Alternatively, the court may rule in favor of the generic firm, allowing them to launch their product if the patents are deemed invalid or unenforceable. In pharmaceutical patent litigation, generic firms filing a paragraph IV ANDA may face patent infringement suits from brand-name drug companies. If the court rules in favor of the generic firm, they can launch their product if the patents are deemed invalid or unenforceable. Another resolution involves settlements where the generic firm agrees not to challenge the patent or produce a generic version of the drug in exchange for compensation from the NDA holder. Some commentators have differing opinions on reverse payment settlements in pharmaceutical patent litigation. Some believe these settlements are anticompetitive, while others see them as a way to promote settlement and avoid the expenses of litigation. Reverse payment settlements in pharmaceutical patent litigation serve the goal of resolving disputes peacefully and preserving judicial resources. These settlements involve an exchange of benefits and obligations between rational actors, allowing for the introduction of generic competition before the patent expires. Judge Richard Posner explains that any settlement agreement involves \"compensation\" to the defendant, leading to potential generic competition prior to the patent expiration date. Reverse payment settlements in pharmaceutical patent litigation involve agreements where a generic firm can market a competing product before the patent term ends. These settlements may benefit consumers and are promoted by the dispute settlement procedures of the Hatch-Waxman Act. In traditional patent litigation, the accused infringer may compensate the patent proprietor to avoid infringement consequences. The Hatch-Waxman Act changes the risk balance between the plaintiff-patentee. The Hatch-Waxman Act alters the risk balance in pharmaceutical patent litigation, allowing generic manufacturers to challenge patents without risking infringement damages. This has led to the emergence of reverse payment settlements, where generic firms can enter the market early. In the 2003 Medicare Prescription Drug, Improvement, and Modernization Act, Congress mandated that the DOJ and FTC receive copies of certain patent settlement agreements in the pharmaceutical field. These agreements trigger the notification requirement if they relate to the manufacture, marketing, or sale of brand-name or generic drugs, or the 180-day generic exclusivity period. The Medicare Prescription Drug, Improvement, and Modernization Act mandated that the DOJ and FTC receive copies of certain patent settlement agreements in the pharmaceutical field. These agreements trigger the notification requirement if they relate to the manufacture, marketing, or sale of brand-name or generic drugs, or the 180-day generic exclusivity period. The MMA stipulates that certain agreements are not subject to this filing requirement, such as purchase orders for raw materials, equipment contracts, employment or consulting contracts, and packaging contracts. The FTC reported receiving 140 final resolutions of patent disputes between brand and generic drugs in FY2012, with 40 settlements possibly involving pay-for-delay payments. The MMA imposed a filing obligation on certain patent settlements but did not set substantive standards for their validity. The report discusses how courts have addressed reverse payment settlements in relation to antitrust laws, including the Sherman Act and the Clayton Act. These laws prohibit certain anticompetitive economic conduct, and different courts have reached varying results when applying them to reverse payment settlements. The Sherman Act Section 1 declares illegal any contract, combination, or conspiracy in restraint of trade, interpreted as applying only to unreasonable restraints. The \"rule of reason\" is used to determine if a practice imposes an unreasonable restraint on competition by considering various factors. The rule of reason in antitrust law involves balancing anticompetitive consequences against business justifications. Per se illegality applies to restraints conclusively presumed to be unreasonable and illegal without detailed inquiry. Practices like price fixing and market division are considered per se violations. The \"quick look\" or \"truncated rule of reason\" approach in antitrust law applies when practices similar to per se violations are demonstrated. Courts have differed in their approaches to reverse payment settlements in pharmaceutical patent litigation, with some subjecting them to strict antitrust scrutiny. The Court of Appeals held that a reverse payment settlement agreement between Hoescht Marion Roussel Inc. and Andrx Pharmaceuticals was per se invalid as it was classified as a horizontal agreement, a restraint of trade involving businesses at the same level of competition. Despite early precedent, subsequent Courts of Appeals ruled that reverse payment settlements were permissible as long as they do not exceed the scope of the patent. Valley Drug Co. v. Geneva Pharmaceuticals, Inc. involved agreements Abbott Laboratories reached with generic firms. The Eleventh Circuit reversed a district court's ruling that reverse payment settlements between Abbott Laboratories and generic firms were per se illegal under the Sherman Act. Instead, the Court of Appeals adopted a \"scope of the patent\" approach, allowing such settlements as long as they stay within the patent's scope, are not based on baseless claims of infringement, and were not obtained through fraud. The Court of Appeals for the Third Circuit rejected the scope of the patent test in K-Dur Antitrust Litigation, stating that it improperly restricts antitrust law and goes against the policies of the Hatch-Waxman Act. The court emphasized that the presumption of validity for patents is procedural, not a substantive right, and should not outweigh congressional goals. The Third Circuit rejected the scope of the patent test in K-Dur Antitrust Litigation, stating that it restricted antitrust law and conflicted with the goals of the Hatch-Waxman Act. The court adopted a \"quick rule of reason\" test for evaluating reverse payment settlements, allowing for antitrust review. The Supreme Court agreed to hear the case of Federal Trade Commission v. Actavis, Inc. to determine the legality of such settlements. The Supreme Court ruled that reverse payment settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. Solvay Pharmaceuticals settled with generic firms Actavis and Paddock Laboratories, who received money to delay marketing their products. The FTC charged the parties with unlawfully sharing in Solvay's monopoly profits and abandoning patent challenges. The Supreme Court ruled that reverse payment settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. The District Court rejected the FTC's claims, but the Eleventh Circuit affirmed, stating that such settlements are immune from antitrust attack if within the scope of the patent. However, the Supreme Court reversed this decision in a 5-3 ruling, stating that the anticompetitive effects of the agreement did not immunize it from antitrust scrutiny. The Supreme Court ruled that reverse payment settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. Justice Breyer reasoned that agreements involving patent litigation under the Hatch-Waxman Act may have significant adverse effects on competition, and antitrust legality should be determined by measuring them against procompetitive antitrust policies. The Court emphasized that certain patent-related settlements can violate antitrust laws. The Supreme Court ruled that reverse payment settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. Justice Breyer emphasized that agreements involving patent litigation under the Hatch-Waxman Act may have adverse effects on competition and should be evaluated based on procompetitive antitrust policies. The Court highlighted that certain patent-related settlements can violate antitrust laws by considering traditional antitrust factors such as likely anticompetitive effects, redeeming virtues, market power, and legal considerations related to patents. The structure of the Hatch-Waxman Act was deemed consistent with subjecting reverse payment settlements to antitrust scrutiny. Justice Breyer presented five considerations against the Eleventh Circuit's near-automatic antitrust immunity for reverse payment settlements. These considerations include the risk of anticompetitive effects, inability to justify large payments, potential market power from patents, the court's ability to assess anticompetitive effects, and the possibility of settling disputes without reverse payments. These factors outweigh the strong consideration of favoring settlements in disputes. The Eleventh Circuit's near-automatic antitrust immunity for reverse payment settlements was challenged by Justice Breyer, who argued against presumptive unlawfulness. The Court emphasized that the FTC must establish antitrust liability using traditional methods, considering factors like payment size, independence, and lack of justification. The Supreme Court concluded that the FTC must prove antitrust liability using the rule of reason analysis. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented, suggesting that reverse payment settlements violate antitrust law only in specific circumstances. The dissenters expressed concerns about discouraging generic firms from challenging patents and weakening patent protection for innovators. The Actavis decision does not eliminate the ability to settle litigation under the Hatch-Waxman Act, but parties must carefully structure and explain their agreements. The lower courts are tasked with applying the rule of reason in Hatch-Waxman cases, which may involve complex issues of patent validity and infringement. Congress has various options, including waiting for further judicial developments after the Actavis decision resolved some issues regarding reverse payment settlements. The lower courts are refining case law on reverse payment settlements. Two bills in Congress address this issue, including the Preserve Access to Affordable Generics Act, S. 27, which aims to regulate pharmaceutical patent litigation settlements. The Fair and Immediate Release of Generics Act, S. 504, aims to discourage reverse payment settlements by granting generic firms rights to regulatory exclusivity and enforcing patent challenge decisions within 45 days. The Hatch-Waxman Act requires brand-name drug companies to settle patent litigation with generic firms within 45 days of a challenge. This is important for public health as it balances the need for innovation with increased access to medications. Such settlements, when in line with antitrust principles, can promote medical innovation and benefit consumers."
}